Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Lipton

Showing results (31-40 of 148) with videos related to

Pageof 15
Sort By:
Cancer Treatment Reviews|December 18, 2009
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancerFred Saad, Allan Lipton
Current Opinion in Supportive and Palliative Care|May 22, 2010
Bone-marker levels in patients with prostate cancer: potential correlations with outcomesFred Saad, Allan Lipton
Seminars in Oncology|December 11, 2007
Clinical benefits and considerations of bisphosphonate treatment in metastatic bone diseaseFred Saad, Allan Lipton
Current Opinion in Supportive and Palliative Care|August 10, 2011
Denosumab: benefits of RANK ligand inhibition in cancer patientsAllan Lipton, Ira Jacobs
Oncology Reports|October 11, 2002
Restoration of estrogen responsiveness by blocking the HER-2/neu pathwayLois Witters, Linda Engle, Allan Lipton
Women'S Health (London, England)|October 7, 2009
Managing aromatase inhibitor-associated bone loss in breast cancerAllan Lipton, Michael Gnant, Matti Aapro
Cancer|August 28, 2003
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinomaAllan Lipton, Ming Zheng, John Seaman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
Predicting response to herceptin therapyAllan Lipton, Kim Leitzel, Suhail Ali
Supportive Cancer Therapy|July 18, 2008
Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastasesLuis Costa, Allan Lipton, Robert E Coleman
Oncology Reports|February 10, 2004
Combining flavopiridol with various signal transduction inhibitorsLois M Witters, Abigail Myers, Allan Lipton
Pageof 15

Showing results (31-40 of 148) with videos related to

Sort By:
Pageof 15
Cancer Treatment Reviews|December 18, 2009
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancerFred Saad, Allan Lipton
Current Opinion in Supportive and Palliative Care|May 22, 2010
Bone-marker levels in patients with prostate cancer: potential correlations with outcomesFred Saad, Allan Lipton
Seminars in Oncology|December 11, 2007
Clinical benefits and considerations of bisphosphonate treatment in metastatic bone diseaseFred Saad, Allan Lipton
Current Opinion in Supportive and Palliative Care|August 10, 2011
Denosumab: benefits of RANK ligand inhibition in cancer patientsAllan Lipton, Ira Jacobs
Oncology Reports|October 11, 2002
Restoration of estrogen responsiveness by blocking the HER-2/neu pathwayLois Witters, Linda Engle, Allan Lipton
Women'S Health (London, England)|October 7, 2009
Managing aromatase inhibitor-associated bone loss in breast cancerAllan Lipton, Michael Gnant, Matti Aapro
Cancer|August 28, 2003
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinomaAllan Lipton, Ming Zheng, John Seaman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
Predicting response to herceptin therapyAllan Lipton, Kim Leitzel, Suhail Ali
Supportive Cancer Therapy|July 18, 2008
Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastasesLuis Costa, Allan Lipton, Robert E Coleman
Oncology Reports|February 10, 2004
Combining flavopiridol with various signal transduction inhibitorsLois M Witters, Abigail Myers, Allan Lipton
Pageof 15